« Back to Record
Citation APA

Rugo, H. H., Tolaney, S. S., Loirat, D., Punie, K., Bardia, A., Hurvitz, S., O'Shaughnessy, J., Cortes, J., Diéras, V., Carey, L. L., Gianni, L., Piccart-Gebhart, M., Loibl, S., Goldenberg, D. D., Hong, Q., Olivo, M. M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer, 8(1), 98. doi:10.1038/s41523-022-00467-1


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/350433

Rugo, H. H., Tolaney, S. S., Loirat, D., Punie, K., Bardia, A., Hurvitz, S., O'Shaughnessy, J., Cortes, J., Diéras, V., Carey, L. L., Gianni, L., Piccart-Gebhart, M., Loibl, S., Goldenberg, D. D., Hong, Q., Olivo, M. M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer, 8(1), 98. doi:10.1038/s41523-022-00467-1